Antitumor Efficacy of Temozolomide in Patients with Metastatic Pulmonary Carcinoids Abstract #1537

Introduction: Temodal (TMZ) is an oral alternative to dacarbazine.
Aim(s): The aim of this study was to retrospectively analyze the efficacy and safety of TMZ in patients with metastatic pulmonary carcinoids (mPC).
Materials and methods: 34 patients pathologically reviewed mPC according to the WHO criteria, referred to Gustave Roussy from 1993 to 2014 were included. Treatment was given at a dose of 150 mg/m2/day for 5 days (D1=D28), escalated to 200 mg/m2/day if well tolerated. Disease control rate, according to RECIST at 12 months was the primary endpoint. DCR was compared in patients who received both oxaliplatin-based chemotherapy (O-BC) i.e gemox or folfox, and dacarbazine (TMZ or deticene/DTIC-BC) in a subgroup of 16 patients referred to Gustave Roussy or Hospices Civils of Lyon.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: Diana Bello Roufai

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1499 Efficacy of the Combination of Capecitabine and Temozolomide in Patients with Advanced Pulmonary Carcinoid Tumours
Introduction: Limited treatment options exist for patients (pts) with advanced pulmonary carcinoids (PC). Capecitabine-temozolomide (CAPTEM) has demonstrated significant efficacy in pts with pancreatic neuroendocrine tumours. However, its role in PC remains unexplored.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: MD, PhD Georgios Papaxoinis
#1080 Evaluation of the Combination Oxaliplatin and 5-Fluorouracil or Gemcitabine in Patients with Metastatic Lung Carcinoid Tumors
Introduction: -
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - Chemotherapy
Presenting Author: MD, PhD Thomas Walter
Keywords: gemox, folfox, lung, carcinoid
#1244 Everolimus in Progressive Metastatic Pancreatic Neuroendocrine Tumors: Analyses of Median Progression Free Survival and Safety in the Real Life Setting
Introduction: Everolimus is an oral inhibitor of mammalian target of rapamycin(mTOR) with antitumor activity in patients(pts) with pancreatic neuroendocrine tumor(pNET)s
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - Targeted therapies
Presenting Author: Michela Del Prete
#1298 Temozolomide-based Second-line Chemotherapy in Patients with Advanced Bronchopulmonary Neuroendocrine Tumours
Introduction: The management of advanced Bronchopulmonary Neuroendocrine Tumours (BP-NET) is not standardized. There are only few clinical studies of Temozolomide (TMZ) as monotherapy or in combination with other agents available for BP-NET.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: PhD Elizaveta Tabaksblat
Authors: Tabaksblat E, Ladekarl M, ...
#737 Impact of Ki-67 Proliferative Index on Survival in Patients with Typical and Atypical Pulmonary Carcinoids
Introduction: Currently pulmonary carcinoids are separated into typical and atypical tumors based on mitotic count and presence of necrosis, according to the WHO classification. Whereas for GEP NETs the ENETS Guidelines have been incorporated into the WHO classification and grading is based on mitotic counts and Ki-67 index, the use of the Ki-67 index for grading pulmonary carcinoids is still under debate.
Conference: 10th Annual ENETS Conference (2013)
Category: Surgical treatment
Presenting Author: Dr Martina Rudelius
Close
Notice
Important Notice:

In preparation of the upcoming ENETS Barcelona 2018 Annual Conference, we have discovered in the world wide web at least one professional entity suggestive of possessing an ENETS mandate for conference registrations. Therefore, we must inform you that 100% of all conference participants are registered through ENETS official website www.enets.org and http://enetsconference.org/. There are no further options to validly register for Barcelona 2018 (or for any other ENETS event).

Please stay away from fraudulent scams abusing the ENETS acronym to register – and charge you above official ENETS conference fees! Such entities, against whom ENETS presses criminal charges, are neither authorized, nor commissioned nor instructed by ENETS to make such representations.